Direct Oral Anticoagulants Exhibit Lower Risks of Mortality and Bleeding Compared to Vitamin K Antagonists in Atrial Fibrillation Patients on Chronic Hemodialysis: A Systematic Review and Meta-Analysis
- 11 July 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Cardiology in Review
Abstract
This meta-analysis aimed to assess the outcomes of patients with atrial fibrillation undergoing chronic hemodialysis, comparing the effectiveness of direct oral anticoagulants (DOACs) and vitamin K antagonists. A systematic search was conducted across various databases including PubMed, Embase, and Google Scholar. Efficacy outcomes focused on the risk of stroke and mortality, whereas safety outcomes assessed the risk of bleeding. Review Manager generated forest plots for data synthesis. Statistical significance was set at P < 0.05, and random-effects models were used. Subgroup analysis identified the sources of heterogeneity. Nine studies met the inclusion criteria for the final analysis. The risk of all-cause stroke [risk ratio (RR): 0.64; 95% confidence interval (CI): 0.51–0.81; P = 0.0001; I 2 = 0%], ischemic stroke (RR: 0.53; 95% CI: 0.29–0.96; P = 0.04; I 2 = 0%), all-cause mortality (RR: 0.73; 95% CI: 0.60–0.88; P = 0.001; I 2 = 71%), major bleeding (RR: 0.63; 95% CI: 0.52–0.76; P < 0.00001; I 2 = 44%), gastrointestinal bleeding (RR: 0.67; 95% CI: 0.53-0.85; P = 0.0009; I 2 = 36%), intracranial hemorrhage (RR: 0.57; 95% CI: 0.38–0.84; P = 0.004; I 2 = 0%) were lower in the DOAC group compared with the vitamin K antagonist group. The risk of cardiovascular-related death (RR: 1.34; 95% CI: 0.69–2.60; P = 0.39; I 2 = 0%), clinically relevant nonmajor bleeding (RR: 0.90; 95% CI: 0.75–1.08; P = 0.26; I 2 = 28%), and hemorrhagic stroke (RR: 0.36; 95% CI: 0.06–2.24; P = 0.28; I 2 = 10%) showed no significant differences. In conclusion, the risks of all-cause stroke, ischemic stroke, all-cause mortality, major bleeding, gastrointestinal bleeding, and intracranial hemorrhage in patients with atrial fibrillation undergoing chronic hemodialysis were lower in the DOAC group.Keywords
This publication has 34 references indexed in Scilit:
- Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysisEuropean Journal of Internal Medicine, 2023
- Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort StudyAmerican Journal of Kidney Diseases, 2022
- Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist’s perspectiveJournal Of Nephrology, 2020
- Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational StudiesDrug Safety, 2019
- Safety and effectiveness of apixaban compared to warfarin in dialysis patientsResearch and Practice in Thrombosis and Haemostasis, 2018
- Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillationJournal of Thrombosis and Thrombolysis, 2016
- Pros and Cons of Vitamin K Antagonists and Non–Vitamin K Antagonist Oral AnticoagulantsSeminars in Thrombosis and Hemostasis, 2015
- Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney DiseaseNew England Journal of Medicine, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapyKidney International, 2010